Glycochenodeoxycholic acid (GCDC, Glycodeoxycholate, Deoxycholylglycine) is a bile salt that is used as an anionic detergent to solubilize lipids.

Glycolaldehyde dimer (2,5-Dihydroxy-1,4-dioxane, 1,4-Dioxane-2,5-diol, DD) is an active endogenous metabolite that appears moderate absorbent and fluorescent, when it reacts with glycine (Gly)/ammonium sulfate (AS).

Glycolic acid (dicarbonous acid, hydroxyacetic acid, hydroacetic acid) is the smallest alpha-hydroxy acid. Due to its excellent capability to penetrate skin, glycolic acid is often used in skin care products, most often as a chemical peel. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

A unique collection of 430 glycolysis related compounds used for high throughput screening(HTS) and high content screening(HCS).

Glycopyrrolate (Glycopyrronium, Robinul, Gastrodyn) is a muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.

Glycopyrrolate (Glycopyrronium, Robinul, Gastrodyn) is a muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.

Glycoursodeoxycholic acid (Ursodeoxycholyl Glycine, Glycine ursodeoxycholic acid) is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment.

Glycyl-l-leucine is a dipeptide that appears to be a common substrate for glycyl-leucine dipeptidase.

Glycyl-L-valine (H-Gly-Val-OH, Glycylvaline) is a dipeptide composed of glycine and valine. It is an incomplete breakdown product of protein digestion or protein catabolism.

Glycylglycine (Diglycine, Diglycocoll, Glycine dipeptide), the simplest peptide made of two glycine molecules, is usually used in the synthesis of more complicated peptides.

Glycyrrhetinic acid is a triterpenoid aglycone component of the natural product glycyrrhizinic acid and possesses remarkable anti-proliferative and apoptosis-inducing activity in various cancer cell lines.

Glycyrrhetinic acid is a triterpenoid aglycone component of the natural product glycyrrhizinic acid and possesses remarkable anti-proliferative and apoptosis-inducing activity in various cancer cell lines.

Glycyrrhizin (NSC 167409, Glycyrrhizic Acid) is a direct HMGB1(high mobility group box 1) inhibitor that inhibits HMGB1-dependent inflammatory molecule expression and oxidative stress; modulates P38 and P-JNK but not p-ERK signalling; Also inhibits 11 beta-hydroxysteroid dehydrogenase and monoamine oxidase (MAO).

Glycyrrhizin (NSC 167409, Glycyrrhizic Acid) is a direct HMGB1(high mobility group box 1) inhibitor that inhibits HMGB1-dependent inflammatory molecule expression and oxidative stress; modulates P38 and P-JNK but not p-ERK signalling; Also inhibits 11 beta-hydroxysteroid dehydrogenase and monoamine oxidase (MAO).

Glycyrrhizin (NSC 167409, Glycyrrhizic Acid) is a direct HMGB1(high mobility group box 1) inhibitor that inhibits HMGB1-dependent inflammatory molecule expression and oxidative stress; modulates P38 and P-JNK but not p-ERK signalling; Also inhibits 11 beta-hydroxysteroid dehydrogenase and monoamine oxidase (MAO).

Glycyrrhizin (NSC 167409, Glycyrrhizic Acid) is a direct HMGB1(high mobility group box 1) inhibitor that inhibits HMGB1-dependent inflammatory molecule expression and oxidative stress; modulates P38 and P-JNK but not p-ERK signalling; Also inhibits 11 beta-hydroxysteroid dehydrogenase and monoamine oxidase (MAO).

GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.

GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.

GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.

GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.

Glyoxylic acid monohydrate (2,2-Dihydroxyacetic acid) is an atmospherically relevant ketoacid.

GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.

GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.

GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.

GMX1778 is a potent and specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with IC50 and Kd of < 25 nM and 120 nM, respectively. GMX1778 induces programmed cell death with apoptotic features. Phase 1.

GMX1778 is a potent and specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with IC50 and Kd of < 25 nM and 120 nM, respectively. GMX1778 induces programmed cell death with apoptotic features. Phase 1.

GNE-0877 (DNL201) is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki of 0.7 nM.

GNE-317 is a potent, brain-penetrant PI3K inhibitor.

GNE-317 is a potent, brain-penetrant PI3K inhibitor.

GNE-317 is a potent, brain-penetrant PI3K inhibitor.

GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with an IC50 of 4 nM for PI3Kα and Kiapp of 21 nM for mTOR.

GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with an IC50 of 4 nM for PI3Kα and Kiapp of 21 nM for mTOR.

GNE-493 (compound 5) is a potent, selective and orally available dual inhibitor of pan-PI3-kinase and mTOR with IC50 of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively.

GNE-617 is a highly potent inhibitor of NAMPT activity with an IC50 of 5 nM.

GNE-617 is a highly potent inhibitor of NAMPT activity with an IC50 of 5 nM.

GNE-781 (compound 19) is an orally active, highly potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP) with IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50 of 6.2 nM and 5100 nM, respectively. GNE-781 exhibits antitumor activity.

GNE-781 (compound 19) is an orally active, highly potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP) with IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50 of 6.2 nM and 5100 nM, respectively. GNE-781 exhibits antitumor activity.

GNE-781 (compound 19) is an orally active, highly potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP) with IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50 of 6.2 nM and 5100 nM, respectively. GNE-781 exhibits antitumor activity.

GNE-781 (compound 19) is an orally active, highly potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP) with IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50 of 6.2 nM and 5100 nM, respectively. GNE-781 exhibits antitumor activity.

GNE-7915 is a highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor, with IC50 and Ki of 9 nM and 1 nM, respectively.